Melanoma antigen peptide and uses thereof
The present invention relates to novel melanoma antigen peptides and specific T lymphocytes directed to said peptides and the use thereof for treating melanoma.
1. A melanoma antigen peptide
having an amino acid sequence that is less than 50 amino acids in length and comprising SEQ ID NO:3:
(SEQ ID NO: 3)
RX 2 PPKPPLX 9
wherein X 2 is cysteine, leucine, methionine, valine, isoleucine or glutamine and X 9 is alanine, valine or leucine.
2. A melanoma antigen peptide according to claim 1 , wherein said melanoma antigen peptide is MELOE-2 having the sequence SEQ ID NO: 5.
3. A melanoma antigen peptide according to claim 1 , wherein said melanoma antigen peptide is selected in the group consisting of peptides having the sequence SEQ ID NO: 21 to SEQ ID NO: 38.
4. A MHC/peptide multimer comprising a melanoma antigen peptide according to claim 3 .
5. An immunising composition comprising
at least one melanoma antigen peptide according to claim 1 .